Results 1 to 10 of about 10,439 (111)

Early PCSK9 Inhibitor Use Correlates With Improved Outcomes in Patients With Acute Stroke Receiving Endovascular Therapy [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background The clinical benefits of early PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor use in patients with acute large vessel occlusion undergoing endovascular therapy (EVT) remain unclear.
Tong Wu, Xiaolin Zhao, Mengxuan Xiao, Junlin Deng, Ziyu Chen, Daihong Cheng, Suyue Pan, Xianghong Liu, Yongming Wu, Kaibin Huang   +9 more
doaj   +2 more sources

PCSK9 Inhibitor Use in the Real World: Data From the National Patient‐Centered Research Network

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors effectively lower LDL (low‐density lipoprotein) cholesterol and have been shown to reduce cardiovascular outcomes in high‐risk patients.
Alanna M. Chamberlain, Yan Gong, Kathryn McAuliffe Shaw, Jiang Bian, Wen‐Liang Song, MacRae F. Linton, Vivian Fonseca, Eboni Price‐Haywood, Emily Guhl, Jordan B. King, Rashmee U. Shah, Jon Puro, Elizabeth Shenkman, Pamala A. Pawloski, Karen L. Margolis, Adrian F. Hernandez, Rhonda M. Cooper‐DeHoff   +16 more
doaj   +3 more sources

PCSK9 Inhibitor Use and the Risk of Age-Related Macular Degeneration in Patients with Atherosclerotic Cardiovascular Disease [PDF]

Pharmaceuticals
Background/Objectives: Emerging evidence suggests that alterations in lipid metabolism may play a contributing role in the pathogenesis of age-related macular degeneration (AMD).
Hou-Ren Tsai, Ji-Ze Hsu, Ching-Hui Loh, Huei-Kai Huang   +3 more
doaj   +2 more sources

A small-molecule inhibitor of PCSK9 transcription ameliorates atherosclerosis through the modulation of FoxO1/3 and HNF1α

EBioMedicine, 2020
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted protein that down-regulates hepatic low-density lipoprotein receptor (LDLR) by binding and shuttling LDLR to lysosomes for degradation.
Xuelei Wang, Xiaofang Chen, Xiumin Zhang, Chunyan Su, Mengxia Yang, Wei He, Yu Du, Shuyi Si, Li Wang, Bin Hong   +9 more
doaj   +3 more sources

PCSK9 inhibitor alleviates experimental pulmonary fibrosis-induced pulmonary hypertension via attenuating epithelial-mesenchymal transition by suppressing Wnt/β-catenin signaling in vivo and in vitro [PDF]

Frontiers in Medicine
BackgroundThe co-occurrence of pulmonary hypertension (PH) in patients with pulmonary fibrosis (PF) is linked to a more unfavorable prognosis and increased mortality compared to PF cases without PH.
Jiancheng Lin, Jiancheng Lin, Jiancheng Lin, Zetao Pan, Zetao Pan, Zetao Pan, Jiayan Sun, Jiayan Sun, Jiayan Sun, Xiaowan Wang, Xiaowan Wang, Xiaowan Wang, Di Yin, Di Yin, Di Yin, Cunyang Huo, Cunyang Huo, Cunyang Huo, Qiang Guo, Qiang Guo, Qiang Guo, Qiang Guo   +21 more
doaj   +2 more sources

PCSK9 inhibitor effectively alleviated cognitive dysfunction in a type 2 diabetes mellitus rat model [PDF]

PeerJ
Background The incidence of diabetes-associated cognitive dysfunction (DACD) is increasing; however, few clinical intervention measures are available for the prevention and treatment of this disease.
Yang Yang, Yeying Wang, Yuwen Wang, Tingyu Ke, Ling Zhao   +4 more
doaj   +3 more sources

Causal relationship between PCSK9 inhibitor and common neurodegenerative diseases: A drug target Mendelian randomization study [PDF]

Brain and Behavior
Background In addition to lowering cholesterol levels, the proprotein convertase subtilis kexin 9 (PCSK9) inhibitor has a variety of effects, including anti‐neuroapoptosis.
Qiang Huang, Qin Zhang, Bei Cao
doaj   +2 more sources

Adoption of PCSK9 Inhibitors Among Patients With Atherosclerotic Disease

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors represent a promising class of lipid‐lowering therapy, although their use has been limited by cost concerns.
Elias J. Dayoub, Lauren A. Eberly, Ashwin S. Nathan, Sameed Ahmed M. Khatana, Srinath Adusumalli, Ann Marie Navar, Jay Giri, Peter W. Groeneveld   +7 more
doaj   +1 more source

Causal relationship between PCSK9 inhibitor and autoimmune diseases: a drug target Mendelian randomization study

Arthritis Research & Therapy, 2023
Background In addition to decreasing the level of cholesterol, proprotein convertase subtilis kexin 9 (PCSK9) inhibitor has pleiotropic effects, including immune regulation. However, the impact of PCSK9 on autoimmune diseases is controversial. Therefore,
Weijia Xie, Jiaxin Li, Hao Du, Jian Xia
doaj   +1 more source

PCSK9 regulates the efficacy of immune checkpoint therapy in lung cancer

Frontiers in Immunology, 2023
Proprotein convertase subtilisin/kexin type 9 (PCSK9) secreted by tumors was reported as a deleterious factor that led to the reduction of lymphocyte infiltration and the poorer efficacy of ICIs in vivo.
Xiang Gao, Xiang Gao, Ling Yi, Chang Jiang, Shuping Li, Xiaojue Wang, Bin Yang, Weiying Li, Nanying Che, Jinghui Wang, Jinghui Wang, Hongtao Zhang, Shucai Zhang   +12 more
doaj   +1 more source